Abstract
THE neuroleptics, comprised primarily of phenothiazines, butyrophenones and thioxanthenes, represent the major drugs used in treating schizophrenic symptoms. For several reasons, routine monitoring of patient blood levels of neuroleptics would be desirable. The dose requirement for therapeutic response varies markedly, related in major part to a wide range in blood levels1–4. Because the severe motor side effect of tardive dyskinesia5 may be very long-lasting and is apparently dose related, patients should be maintained on the lowest dose required for therapeutic efficacy5,6. While blood levels must exceed a threshold to elicit symptomatic improvement, too high a blood level may reduce the therapeutic response7–9. The available assays for plasma neuroleptics, including gas chromatography, fluorimetry, formation of radiolabelled derivatives4,10–14 and radioimmunoassay15,16 have not attained routine clinical use because of technical complexities or restrictions of specificity to single drugs. We describe here an assay for neuroleptics based on competition for dopamine receptor binding which is simple, sensitive, specific and suitable for routine clinical application.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Curry, S. H., Davis, J. M. & Janowsky, D. S. Archs gen. Psychiat. 22, 209–215 (1970).
Garver, D. L. et al. Archs gen. Psychiat. 33, 862–866 (1976).
Cressman, W. A., Bianchine, J. R., Slotnick, V. B., Johnson, P. C. & Plostneiks, S. J. Eur. J. clin. Pharmac. 7, 99–103 (1974).
Forsman, A., Martensson, E., Nyberg, G. & Ohman, R. Nauyn-Schmiedeberg's Arch. Pharmac. 286, 113–124 (1974).
Kobayashi, R. M. New Engl. J. Med. 296, 257–260 (1977).
American College of Neuropsychopharmacology—F.D.A. Task Force, New Eng. J. Med. 289, 20–23 (1973).
Curry, S. H., Marshall, J. H. L., Davis, J. M. & Janowsky, D. S. Archs gen. Psychiat. 22, 289–296 (1970).
Rivera-Calimlim, L., Nasrallah, H., Straus, J. & Lasagna, L. Am. J. Psychiat. 133, 646–652 (1976).
Garver, D. L., Dekirmenjian, H., Davis, J. M., Cooper, R. & Erickson, S. Am. J. Psychiat. 134, 304–307 (1977).
Usdin, E. CRC Crit. Rev. clin. Lab. Sci. 2, 347–391 (1971).
Marcucci, F., Airoldi, L., Mussini, E. & Garattini, S. J. Chromatogr. 59, 174–177 (1971).
Zingales, I. A. J. Chromatogr. 54 15–24 (1971).
Alfredsson, G., Wode-Helgodt, B. & Sedvall, G. Psychopharmacologia 48, 123–131 (1976).
Rivera-Calimlim, L. & Siracusa, A. Commun. Psychopharmac. 1, 233–242 (1977).
Kawashima, K., Dixon, R. & Spector, S. Eur. J. Pharmac. 32, 195–202 (1975).
Clark, B. R., Tower, B. B. & Rubin, R. T. Life Sci. 20, 319–326 (1977).
Snyder, S. H., Banerjee, S. P., Yamamura, H. I. & Greenberg, D. A. Science 184, 1243–1253 (1974).
Iversen, L. L. Science 188, 1084–1089 (1975).
Creese, I., Burt, D. R. & Snyder, S. H. Science 194, 481–483 (1976).
Creese, I., Burt, D. R. & Snyder, S. H. Science 194, 546 (1976).
Seeman, P., Lee, T., Chau-Wong, M. & Wong, K. Nature 261, 717–719 (1976).
Creese, I., Schneider, R. & Snyder, S. H. Eur. J. Pharmac. (in the press).
Curry, S. H. J. Pharm. Pharmac. 22, 193–197 (1969).
Bickel, M. H. J. Pharm. Pharmac. 27, 733–738 (1975).
Janssen, P. A. J. & Allewijn, F. T. N. Arzneim. Forsch. 19, 199–208 (1969).
Burt, D. R., Creese, I. & Snyder, S. H. Molec. Pharmac. 12, 800–812 (1976).
Sakalis, G., Chan, T. L., Gershon, S. & Park, S. Psychopharmacologia 32, 279–284 (1973).
Creese, I., Manian, A. A., Prosser, T. D. & Snyder, S. H. Eur. J. Pharmac. (in the press).
Shostak, M. & Perel, J. M. Fedn Proc. 35, 531 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
CREESE, I., SNYDER, S. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270, 180–182 (1977). https://doi.org/10.1038/270180a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/270180a0
This article is cited by
-
Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia—a systematic review of the literature
Psychopharmacology (2019)
-
Concurrence of cortex and platelet serotonin2 receptor binding characteristics in the individual and the putative regulation by serotonin
Journal of Neural Transmission (1993)
-
Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: Window to the brain?
Amino Acids (1992)
-
A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites
Psychopharmacology (1989)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.